Co-precipitation for Homogeneous PEG Medical Adhesive Blends
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing polyethylene glycol (PEG) based medical adhesives, sealants, and barriers lack efficient processes for creating homogeneous blends that ensure uniform properties and controlled degradation, release rates, and integration of therapeutic agents without adverse reactions or systemic toxicity.
Innovation Solution
The co-precipitation method involves dissolving PEG cross-linker and additional molecules in solvents like methanol or DMSO, followed by precipitation to form a homogenous powder, allowing for the incorporation of functionalized PEG, therapeutic agents, and colorants like Indocyanine Green, which enhances homogeneity, flowability, and controlled release properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional blending methods are used to prepare PEG-based medical adhesives, then the process is simpler, but the homogeneity and uniformity of the blend are insufficient
Solution Approach 1:
The patent applies parameter changes by controlling precipitation conditions including temperature, solvent composition, and addition rate to achieve homogeneous PEG blends. The process parameters such as cooling rate and solvent ratio are optimized to ensure uniform distribution of PEG and additives in the final product.
Solution Approach 2:
The patent uses solvents as intermediary substances to facilitate the blending process. The solvent system mediates between PEG and additives, allowing them to dissolve and mix uniformly before precipitation, thereby achieving homogeneous blends without direct mechanical mixing of incompatible materials.
2Manufacturing precision
If PEG and additives are blended without co-precipitation, then the process is faster, but the distribution uniformity of therapeutic agents is poor
Solution Approach 1:
The patent applies preliminary action by dissolving PEG and therapeutic agents in a solvent system before precipitation. This preliminary dissolution step ensures that all components are uniformly distributed at the molecular level before the final product forms, achieving homogeneous distribution of therapeutic agents without requiring extended mixing times.
Solution Approach 2:
The patent utilizes phase transitions by controlling the precipitation process from dissolved state to solidified blend. The controlled phase transition during precipitation ensures uniform distribution of therapeutic agents as the solution transforms into a homogeneous solid product, maintaining production efficiency while achieving excellent distribution uniformity.
3Reliability
If traditional mixing methods are used, then equipment requirements are lower, but the controlled release properties are inconsistent
Solution Approach 1:
The patent applies parameter changes by controlling precipitation conditions including temperature, solvent composition, and addition rate to achieve homogeneous PEG blends. The process parameters such as cooling rate and solvent ratio are optimized to ensure uniform distribution of PEG and additives in the final product.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method produces PEG blends with improved homogeneity, reduced variability, and consistent properties, facilitating easier handling and processing, while maintaining or enhancing the burst pressure, degradation, and elastic modulus of medical adhesives, ensuring safe and effective absorption without adverse reactions.
Implementation Method 1
dissolving PEG cross-linker and additional molecules in solvents like methanol or DMSO
Implementation Method 2
followed by precipitation to form a homogenous powder
Data Source
AI summary
Methods for preparing a PEG composition by co-precipitation of two or more components to produce a substantially homogenous powder. According to some embodiments, the two or more components are at least and partially soluble in a solvent, and at least one component is a functionalized PEG. Contacting the at least two component with the solvent at least partially dissolves the components which are then co-precipitated. The resulting product is substantially homogenous, unlike product made by other methods. The PEG composition may be co-precipitated with additional compounds, such as a colorant like indocyanine green.